Patel Sanj K — SEC insider filings
SEC reporting owner CIK 1532218. 41 insider filings on record with FilingPulse; latest filed 2026-11-06.
Transaction summary — filings shown
Covers all 41 filings on record, filed 2020-09-14 to 2026-11-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 58 legs across 16 filings — 2,092,283 shares, $107,758,772 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 185.
- Largest priced transaction: sale of 145,708 shares @ $93.53 ($13,628,069) in Kiniksa Pharmaceuticals International, plc, filed 2026-11-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | CHAIRMAN & CEO, Director | 41 | — | 58 legs · 2,092,283 sh · $107,758,772 | 185 |
Insider filings — Patel Sanj K
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-06 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 145,763 @ $17.92 · Sale (S): 1,460 @ $92.35 · Sale (S): 11,335 @ $93.54 · Sale (S): 81,742 @ $94.20 · Sale (S): 29,845 @ $95.48 · Sale (S): 26,918 @ $96.05 · +1 more | EDGAR |
| 2026-11-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 47,530 @ $8.83 · Sale (S): 41,169 @ $92.01 · Sale (S): 18,685 @ $92.77 · Sale (S): 15,903 @ $93.62 · Sale (S): 8,888 @ $94.72 · Sale (S): 4,490 @ $95.97 · +17 more | EDGAR |
| 2026-09-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 9,991 · Option exercise (M): 6,481 · Option exercise (M): 6,237 · Option exercise (M): 8,609 · Tax withholding (F): 15,144 @ $79.28 · Grant/award (A): 30,050 (derivative) @ $0 · +5 more | EDGAR |
| 2026-09-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 9,991 · Option exercise (M): 6,481 · Option exercise (M): 6,237 · Option exercise (M): 8,609 · Tax withholding (F): 15,144 @ $79.28 · Grant/award (A): 30,050 (derivative) @ $0 · +5 more | EDGAR |
| 2026-06-02 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Conversion (C): 900,000 · Conversion (C): 900,000 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 48,565 @ $30.93 · Sale (S): 48,565 @ $54.02 · Option exercise (M): 48,565 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 431,904 @ $10.36 · Option exercise (M): 51,750 @ $30.93 · Sale (S): 74,635 @ $50.43 · Sale (S): 113,673 @ $51.47 · Sale (S): 243,596 @ $52.02 · Sale (S): 51,750 @ $54.02 · +8 more | EDGAR |
| 2026-04-08 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 7,278 @ $10.36 · Sale (S): 7,278 @ $50.01 · Option exercise (M): 9,991 · Tax withholding (F): 4,831 @ $48.94 · Option exercise (M): 7,278 (derivative) @ $0 · Option exercise (M): 9,991 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 21,327 · Tax withholding (F): 10,313 @ $48.13 · Grant/award (A): 120,150 (derivative) @ $0 · Grant/award (A): 30,050 (derivative) @ $0 · Grant/award (A): 60,100 (derivative) @ $0 · Option exercise (M): 6,481 (derivative) @ $0 · +2 more | EDGAR |
| 2025-11-14 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Gift (G): 111,794 @ $0 · Gift (G): 111,794 @ $0 · Gift (G): 60,000 @ $0 · Gift (G): 60,000 @ $0 | EDGAR |
| 2025-10-22 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 121,248 @ $3.80 · Sale (S): 98,934 @ $38.81 · Sale (S): 22,314 @ $39.32 · Option exercise (M): 39,331 @ $3.80 · Sale (S): 39,331 @ $38.77 · Option exercise (M): 97,390 @ $3.80 · +4 more | EDGAR |
| 2025-09-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 6,238 · Option exercise (M): 6,481 · Option exercise (M): 9,992 · Tax withholding (F): 10,983 @ $33.49 · Option exercise (M): 6,569 · Tax withholding (F): 3,177 @ $34.28 · +6 more | EDGAR |
| 2025-05-28 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 4,837 @ $1.59 · Sale (S): 4,837 @ $27 · Option exercise (M): 19,317 @ $1.59 · Sale (S): 19,317 @ $27.01 · Option exercise (M): 62,116 @ $1.59 · Sale (S): 62,116 @ $27.33 · +3 more | EDGAR |
| 2025-05-22 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 2,349 @ $1.59 · Sale (S): 2,349 @ $27.02 · Option exercise (M): 2,349 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 2,872 @ $1.59 · Sale (S): 2,872 @ $27.03 · Option exercise (M): 2,872 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 1,965 @ $1.59 · Sale (S): 1,965 @ $27 · Option exercise (M): 101 @ $1.59 · Sale (S): 101 @ $27 · Option exercise (M): 6,029 @ $1.59 · Sale (S): 6,029 @ $27.05 · +3 more | EDGAR |
| 2025-05-05 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Grant/award (A): 7,987 (derivative) @ $0 · Grant/award (A): 8,386 (derivative) @ $0 · Grant/award (A): 12,910 (derivative) @ $0 · Grant/award (A): 13,328 (derivative) @ $0 | EDGAR |
| 2025-04-09 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 9,992 · Tax withholding (F): 4,832 @ $20.28 · Option exercise (M): 9,992 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 6,481 · Option exercise (M): 6,238 · Tax withholding (F): 2,304 @ $21.77 · Tax withholding (F): 3,017 @ $21.77 · Grant/award (A): 137,638 (derivative) @ $0 · Grant/award (A): 34,435 (derivative) @ $0 · +3 more | EDGAR |
| 2025-03-19 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 6,569 · Tax withholding (F): 2,004 @ $22.61 · Option exercise (M): 6,569 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 89,561 @ $1.59 · Sale (S): 89,561 @ $23 · Option exercise (M): 89,561 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 16,474 · Tax withholding (F): 7,967 @ $26.74 · Option exercise (M): 6,569 · Tax withholding (F): 3,177 @ $26.74 · Grant/award (A): 24,950 (derivative) @ $0 · Grant/award (A): 129,750 (derivative) @ $0 · +3 more | EDGAR |
| 2024-07-25 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 136,124 @ $1.59 · Sale (S): 23,075 @ $23.25 · Sale (S): 50,000 @ $25.05 · Sale (S): 63,049 @ $27.01 · Option exercise (M): 136,124 (derivative) @ $0 | EDGAR |
| 2024-04-08 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 9,992 · Tax withholding (F): 4,075 @ $17.90 · Grant/award (A): 129,750 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 24,950 (derivative) @ $0 · Option exercise (M): 9,992 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 6,482 · Tax withholding (F): 1,903 @ $19.70 · Option exercise (M): 6,482 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Sale (S): 65,012 @ $21.02 | EDGAR |
| 2024-03-06 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Sale (S): 9,406 @ $21.31 · Sale (S): 3,336 @ $22 · Sale (S): 5,582 @ $21 | EDGAR |
| 2023-09-06 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 9,992 · Tax withholding (F): 4,432 @ $17.76 · Option exercise (M): 6,569 · Tax withholding (F): 2,187 @ $17.76 · Option exercise (M): 9,992 (derivative) @ $0 · Grant/award (A): 25,925 (derivative) @ $0 · +2 more | EDGAR |
| 2023-04-11 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 9,992 · Tax withholding (F): 2,933 @ $10.71 · Option exercise (M): 9,992 (derivative) @ $0 | EDGAR |
| 2023-04-03 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Grant/award (A): 155,500 (derivative) @ $0 · Grant/award (A): 25,925 (derivative) @ $0 | EDGAR |
| 2023-03-20 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 6,569 · Tax withholding (F): 1,929 @ $11.46 · Option exercise (M): 12,002 · Tax withholding (F): 3,523 @ $11.12 · Option exercise (M): 6,569 (derivative) @ $0 · Option exercise (M): 12,002 (derivative) @ $0 | EDGAR |
| 2022-09-06 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 6,569 · Tax withholding (F): 1,929 @ $11.44 · Grant/award (A): 239,795 (derivative) @ $0 · Grant/award (A): 39,967 (derivative) @ $0 · Option exercise (M): 6,569 (derivative) @ $0 | EDGAR |
| 2022-04-11 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Grant/award (A): 239,795 (derivative) @ $0 · Grant/award (A): 39,967 (derivative) @ $0 | EDGAR |
| 2022-03-23 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 18,555 · Tax withholding (F): 5,446 @ $10.98 · Option exercise (M): 18,555 (derivative) @ $0 | EDGAR |
| 2022-03-18 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 6,569 · Tax withholding (F): 1,922 @ $10.13 · Option exercise (M): 6,569 (derivative) @ $0 | EDGAR |
| 2021-09-07 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Grant/award (A): 157,658 (derivative) @ $0 · Grant/award (A): 26,276 (derivative) @ $0 | EDGAR |
| 2021-03-23 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Grant/award (A): 18,555 (derivative) @ $0 · Grant/award (A): 12,002 (derivative) @ $0 | EDGAR |
| 2021-03-18 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Grant/award (A): 157,658 (derivative) @ $0 · Grant/award (A): 26,276 (derivative) @ $0 | EDGAR |
| 2021-02-10 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 4,924 @ $1.59 · Sale (S): 4,924 @ $23 · Option exercise (M): 20,401 @ $1.59 · Sale (S): 20,401 @ $23.04 · Sale (S): 4,528 @ $23 · Sale (S): 23,569 @ $23.08 · +6 more | EDGAR |
| 2020-10-14 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 872 @ $1.59 · Sale (S): 872 @ $21 · Sale (S): 670 @ $21 · Option exercise (M): 150,700 @ $1.59 · Sale (S): 150,700 @ $21.02 · Sale (S): 99,330 @ $21.02 · +2 more | EDGAR |
| 2020-09-14 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-04 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1532218 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs